While a fraction of FTD cases demonstrate AD pathology [11–14], over 50% of Alzheimer’s cases present with TDP pathology [15–18] rendering AD based biomarkers (p-tau and Aβ) unreliable. The gene discussed is MAPT; the disease is frontotemporal dementia.